DON'T Inject What You Can't Verify: Compounded Peptide Safety Explained

0:00Dr. Gabrielle Lyon:What is the first mistake almost everyone makes? They treat, quote, peptides as one category. And this is where the gap between the internet and the published science is the widest that I've ever seen in my career. I've never seen anything like this. The casual peptide culture, which is something that we've never seen before, leans hard on the phrase absence of evidence is not absence of evidence. And this is true. But the absence of evidence also doesn't give you permission to pretend you know things you don't. People will say GLP-1 are peptides and GLP-1s work. Therefore, peptides work. Well, that's not how evidence works.

0:39Dr. Gabrielle Lyon:The question that we have to come back to is, what does the human data show? Why are we utilizing these peptides? And this episode is not hype and it is not a fear-mongering episode because I don't make those. It's about a single idea that I want you to carry out of here because it will protect you better than anything else that I can give you. Let me walk you through what those human studies showed.

1:08Dr. Gabrielle Lyon:Last week, a patient came to see me and she was convinced that she had finally found that one thing. Now, she wasn't naive. She was an engineer. So very methodical. She had a folder, an actual folder of studies on a peptide she'd been injecting for six months. something that she had ordered online after a man she trusted with real credentials said it had healed his shoulder. She had done her homework and she had done a lot of homework. She had what looked to her like a mountain of evidence. Here's what I had to tell her. That mountain of evidence, over 500 published papers on this compound, comes down to roughly 30 human beings in the study.

1:51Dr. Gabrielle Lyon:Three small pilot trials, essentially one researcher behind most of the human data. Everything else, the other 99 % was done in rats and mice, rodents. She hadn't found a mountain of human proof. She found a plausible mechanism and a proof of concept, which I think is very important. So let me say this clearly up front. I am not anti-peptide. Peptide medicine is one of the most exciting frontiers we have in modern medicine. Some of the most important drugs of the last century are peptides. And this episode is not hype and it is not a fear-mongering episode because I don't make those. It's about a single idea that I want you to carry out of here because it will protect you better than anything else that I can give you.

2:37Dr. Gabrielle Lyon:You have to separate the molecule from the marketplace. The molecule can be brilliant. And the marketplace, well, that can be a little crazy with trends and noise. And we're going to hold on to these two thoughts, the molecule and the marketplace. What is a peptide? A peptide is a short chain of amino acids, my favorite thing, typically somewhere between 2 and 50, linked by what are called peptide bonds. They sit in a unique pharmacological space, bigger and more specific than a small molecule drug. smaller and more nimble than a full protein. That structure in particular is the whole appeal. Peptides can act like a key for one lock, high target specificity, and a well-characterized mechanism of action, and generally lower toxicity than a blunt small molecule drug that hits everything all at once.

3:32Dr. Gabrielle Lyon:It's that precision, the targeted aspect of these peptides. So what is the first mistake almost everyone makes? They treat, quote, peptides as one category. It's not one category. It's a spectrum of where a compound sits on that spectrum. And that's what tells you what you need to know about the peptide. People ask me, what do I think of peptides? Well, my answer is, which category? Which peptides? It's like the equivalent of someone asking me, what do I think of protein? Well, are you asking me if I like steak or fish or pea protein or tofu? Now, at the top, you have an FDA-approved peptide drug class.

4:16Dr. Gabrielle Lyon:And this is rigorously trialed, manufactured under pharmaceutical standards, with their benefits and risks formally characterized in humans. This is where the incretins live, like semaglutide, trisepatide, the GLP-1 class. These medications work. They have done and given people more hope and have transformed the obesity epidemic. And people will say GLP-1 are peptides and GLP-1s work. Therefore, peptides work. Well, that's not how evidence works. Semaglutide is not the same thing as, say, another peptide like samorlin. Take retitrutide or RETA. Still one rung down. It's investigational, not yet improved.

5:04Dr. Gabrielle Lyon:And I am seeing more people take it. I have never seen anything like this in 20 years of medical practice. Now, retitrutide, it's a once-weekly injectable that hits three receptors, GIP, GLP-1, and glucone. In its phase two trial in the New England Journal of Medicine, the 12 milligram group lost an average of 24.2 % of their body weight at 48 weeks. And the weight loss curve still hadn't plateaued. I mean, just like let's pause for a second. That amount of weight loss is extraordinary. Every single person on the 8 to 12 milligram dose lost at least 5%. Now, one note on precision, that 24.2 % was the 48-week secondary endpoint.

6:00Dr. Gabrielle Lyon:The primary endpoint was at 24 weeks. The numbers are still, by the way, extraordinary. But stunning in a trial is not the same as FDA approved. Now, if something is not FDA approved, it doesn't mean it's ineffective. It means unconfirmed through the FDA process that exists. And it exists for a number of reasons. Let's talk about the two old school peptides that have been around forever that are FDA approved. Tessamorlin, brand name Agrifta, is a FDA-approved growth hormone-releasing hormone analog. But it's approved for one narrow thing, reducing visceral fat in people with HIV-associated lipodystrophy.

6:43Dr. Gabrielle Lyon:It is weight neutral. It's not some magic anti-aging drug. And it does carry some warnings. For example, glucose intolerance, elevated IGF-1, fluid retention. And it is contraindicated in active cancer. So that is tesamoralin. That is an FDA-approved peptide that has on-label use and off-label use, which we've spoken about in other podcasts. The second common FDA-approved peptide in many of the anti-aging clinics, et cetera, is samoralin. Samoralin is the second very common FDA-approved peptide. And it's what many of the anti-aging clinics love to call the legal peptide. And it was approved back in the 90s for pediatric growth hormone deficiency.

7:33Dr. Gabrielle Lyon:Then it was pulled from the market in 2008 for business reasons, apparently, not safety. So today it exists only through compounding prescribed off-label for body composition, sleep, and recovery. And the adults in the evidence of the Samorlan trials. From what I see, they are small, short-term studies in older adults. There are some modest changes in body composition. There was a review in 2026 in the Journal of Growth Hormone and IGF Research concluding that stimulating the growth hormone access for, and I quote, somatopause produces only minor body composition changes. No meaningful improvement in health or well-being, and a list of documented side effects.

8:23Dr. Gabrielle Lyon:Now, we had used this off-label many years ago in my practice, and we did not see a ton of great effects. So I can appreciate that. But the question that we have to come back to is, what are we going for? At the end, why are we utilizing these peptides? If they are an incretin, there's very clear outcomes that we're looking for. But what about these other peptides? What does the human data show? Now let's go to the peptides that everybody's actually seems to be asking about. The repair and recovery peptides, peptides like BPC-157, TB-500, the quote Wolverine stack. I'm just waiting for the cougar stack to come out.

9:08Dr. Gabrielle Lyon:And this is where the gap between the internet and the published science is the widest that I've ever seen in my career. I've never seen anything like this. Now, let's go back to the engineers folder and let's open it. A 2025 systematic review in the HSS journal, the Hospital for Special Surgery, which is phenomenal, screened 544 articles on BPC-157 published between 1993 and 2004. And after screening, 36 studies met inclusion criteria. Of those 36, 35 were preclinical in animals. One was clinical in humans, and there's a 99.7 % animal-to-human ratio. And a separate 2026 review concluded that the entire human clinical data set comes from fewer than 30 subjects across three uncontrolled pilot studies with no completed phase two trials.

10:09Dr. Gabrielle Lyon:That is unusual, that ratio of 544 papers and about 30 humans. This is the single most important fact that you need to know before you continue on the trajectory of peptides. Let me walk you through what those human studies showed because I want to be fair to the signal. And, you know, I have my opinion and perspective around all of these things. And, you know, I know some of these compounding pharmacies, and it just seems as if there is policy, and then there is medicine, and then there is patient need. So we're going to come back to all that. To be fair to the signal, knee pain, a small retrospective study of BPC-157 injected directly into the joint for chronic knee pain.

10:58Dr. Gabrielle Lyon:Seven of 12 patients reported relief lasting more than six months. This is a signal. That is major. It is retrospective, meaning they looked to the past. It's uncontrolled. So we can't separate out placebo, which placebo means you believe something works. And it doesn't prove that tissue was repaired. And it used direct joint injection, not subcutaneous shot that people are typically doing at home. interstitial cystitis, which I have seen many times in my clinic, and it's a bladder irritation. A pilot study injected BPC-157 near the site of bladder inflammation in women who'd failed standard treatment and reported near complete symptom resolution in most of them.

11:46Now that is promising, tiny, uncontrolled, but still promising.

11:51Dr. Gabrielle Lyon:Now regarding safety, a 2025 pilot reported IVBPC-157 in two healthy adults with no adverse effects. Two people. Now that's not a safety database, but it is a starting line. Hold both things again. The signal, that is interesting. The evidence still has some ways to go, but those are not contradictory statements. They're the whole point. I also want to be fair and give you the strongest possible case for these compounds, the real one, and I'm going to be as persuasive as I can. So here it goes, the mechanism. The mechanism is genuinely compelling. The mechanism of action of these peptides, it's compelling.

12:34Dr. Gabrielle Lyon:In animal models, BPC-157 does remarkable things. Accelerated healing after Achilles tendon transection. After muscle injury, it appears to upregulate growth hormone receptor expression, drive organized blood vessel growth, and quiet down inflammatory cytokines. Now, if you ask me, that's not nothing. This is biologically fascinating, and it's reproducible across labs. Peptides as a class can do what blunt drugs can't. They hit one pathway with high affinity and leave the rest of your body alone. Insulin and GLP-1 prove the category can change medicine. My old friend, and I don't know if you guys remember the late Charles Poliquin, he introduced me to peptides over a decade ago.

13:27And man, this guy, he was hellbent on that.

13:30Dr. Gabrielle Lyon:And there's also another argument, and it's one that you've probably heard recently because it was made by a board-certified urologist. His name is Dr. Alex Tatum. He's epic. He is, again, board-certified urologist, so an expert in many things, but specifically men's health. And he went on Stephen Bartlett's podcast, spoke to millions of people, and here's what he said. These compounds were quietly restricted by the FDA almost overnight. They're being kept from patients, not because they're dangerous, but because they're threatening a pharmaceutical business model built on patented small molecules.

14:14Peptides are precision tools, they're keys, they're not hammers, and the people who'd benefit, people in chronic pain that nothing else has fixed, are being denied access while the regulatory machinery protects incumbents. Now, on this view, the restrictions are somewhat the scandal and loosening them is patients finally getting their medicine back. And I want to be honest with you, part of this argument is totally right. People reaching for these aren't stupid or vain. They're often in real pain and that medical system failed to fix them. They watched their bodies change and got told to live with it, live with chronic pain or live with X, Y, and Z.

14:58The desperation is totally legitimate and the precision of peptides is a real scientific advantage. And again, we're talking about peptides broadly. I broke down some categories previously. The casual peptide culture, which is something that we've never seen before, leans hard on the phrase absence of evidence is not absence of evidence. And this is true, but the absence of evidence also doesn't give you permission to pretend you know things you don't. Mechanism is biological plausibility. It's not proof. A rat's tendon healing in a lab is not a human athlete returning to sport. Now, the marketplace itself, the FDA is explicit.

15:42Compounded drugs are not FDA approved, which means no one verify their safety, effectiveness, or quality before they reach you. And the specific risks with peptides are not theoretical. There is immunogenicity. Your immune system can react to the compounds or impurities. What is critical here, though, is that choose your compounding pharmacy wisely. Analysis of compounded preparations have found mislabeled concentrations, impurities, and novel peptide fragments. And remember, These are injected. Injection bypasses the body's natural defenses. The lack of oversight isn't a paperwork problem. It's a clinical hazard, and it's a clinical hazard that goes into your bloodstream.

16:32Now, the regulatory ground is shifting, and you need the honest version. In April 2026, the FDA removed about a dozen of these peptides, including BPC-157, from its list of substances raising significant safety concerns. Here's the part the headlines skipped. That didn't happen because of new safety data, which is so important. It happened because the outside parties who nominated them withdrew their requests against a backdrop of policy pressure to restore access. The safety watchdogs and the Institute for Safe Medication Practices put it plainly in a joint white paper. The change was, and I quote, not accompanied by the result of new scientific evidence.

17:19None of the 12 has been adequately tested in humans for what it's actually being sold

17:25Dr. Gabrielle Lyon:for. Now, this is what the FDA is saying. The FDA's advisory committee meets in late July, 2026, so very soon, to weigh going further. So if someone tells you the FDA cleared these, well, let's see. And also a policy lever moved. The evidence didn't. I know a handful of owners of compounding pharmacies, and they tell me they have multiple clinical trials, and we're waiting to get those. I'm hoping that we see those. And really, this is ultimately the deepest problem. The one at 2026 JAMA analysis nailed. Our regulatory tools are reactive. They chase the supply chain, the vendors, the files, the warning letters.

18:05But the real engine isn't the supply chain. It's the demand machine. It's the influencers. it's the algorithms it's the perfectly produced clip that made you want this before you examined who are you getting it from what does it do and you can't regulate a feeling right now that feeling is winning and that's why I didn't land on the access argument not because the molecule has no promise but because the marketplace selling it has no accountability and the demand for it is being manufactured by people. And people want something different, but they don't necessarily or are necessarily prepared for the consequences when it goes wrong.

18:49Meaning if you inject something that isn't safe or inject something that is contaminated. So here's where I stand. I am not anti-peptide. I am anti-carelessness. I am anti-hype. And I'm very much anti-injecting an unknown substance from an unaccountable source because someone confident and good-looking told you. Patient stories matter. Anecdotes matter. They help us spot patterns worth studying. But an anecdote is a hypothesis, not a conclusion. We're in the beginning of science. We're not in a substitution for it. So let's separate the molecule from the marketplace. A peptide can have a beautiful mechanism of action and still reach you through a supply chain that can't promise you what's in the vial.

19:39If something is going into your body, especially through a needle, the standards, they have to be higher than three words on a label that says research use only. The label isn't a credential. It is a liability. So the truth most peptide marketing depends on you not noticing is the people selling you a shortcut are betting you won't do the boring work. Although that engineer did a lot of boring work and we're going to get there. I think we are in a new era of medicine and that is the era of peptide medicine. So if you're going to consider any of these, here are a handful of questions I want you to ask.

20:22I'm going to put this on the screen so that you can screenshot them. Four questions. Run anything, any peptide, any clinic, any confident claim through all four before you get it. Question number one, what is the level of evidence? Is this real? Is this animal data? Is this a case report, a pilot trial, or a phase three program in humans? For BPC-157, the bottleneck isn't biological activity. It's the absence of basic pharmaceutical science, characterized formulations, validated pharmacokinetics, a coherent development plan. And if the answer is mostly rats, then you have to choose. But I do believe it's coming.

21:06Number two, what outcome did the study measure? Less pain is meaningful. It is not the same as an MRI-confirmed tissue repair. Marketing collapses those two consistently. Don't let it. Number three, where is this coming from? Is this peptide coming from a prescribed licensed clinician? Is it compounded by a properly licensed pharmacy? Is there sterility testing? Is it sterile? Is there a legitimate certificate analysis? If you can't answer all of those, then you are not a patient. You are a test subject who paid for the privilege. And finally, number four, are you tested in sport? If you are tested in sport, then you must know if BPC-157 is on the prohibited list.

21:53Since 2022, there is no therapeutic use exemption for some of these peptides. TB-500 is prohibited, BPC-157 is, and athletes have drawn multi-year bans. A legal label from a supplier doesn't mean it's acceptable in a doping panel. So check the current prohibited list yourself every single time. I told you we'd come back to the boring work and here it is. I'm just going to be blunt because this is part of that what actually changes your life. And it's not the part that someone can sell you in a vial. Any advanced therapy, every peptide on that ladder, approved or not, is only as good as the physiology underneath it.

22:35If your foundation is chaos, adding signaling molecule to the chaos doesn't fix it. It just signals into the noise. Before you go looking for a magic bullet, you lock in the three things that are proven in humans every time for free. Mechanical demand, progressive resistance training, that is the most powerful signaling mechanism we have for tissue remodeling and building your muscle, your organ of longevity. No compound replaces the adaptation that load creates, none. And of course, nutritional foundation protein anchored across your day, enough to clear the leucine threshold and drive muscle protein synthesis and frankly, synthesis of just about everything else.

23:21You've got to get your nutrition right. If you skip it, you're not really optimizing anything. Of course, systemic recovery, deep sleep and real recovery. If your inflammation is high because your lifestyle is a mess, the fanciest peptide in the world gives you diminishing returns. And that's it. That's the protocol. That protocol beats just about any vial, and it's one that you have full control over. So back to my engineer with her folder. I didn't tell her she was foolish. I think that she's very hopeful. She wasn't. I told her that what she did was have the right instinct, go to the evidence.

24:00And well, we went back to her foundation. We did the boring work and the boring work with her peptide that she chose. We separated the molecule from the marketplace. And before I knew it, there she was better than ever. And remember, there are no shortcuts for longevity and feeling better. And there's a baseline of proper work that is totally worth it. I'm Dr. Gabrielle Lyon and stay forever strong.